Gilead Sciences Announces 2.6 Percent Increase in First Quarter 2025 Dividend
Gilead Sciences (GILD) has announced a 2.6% increase in its quarterly cash dividend, which will take effect in the first quarter of 2025. The new dividend will be $0.79 per share of common stock, payable on March 28, 2025, to stockholders of record as of March 14, 2025.
The dividend increase demonstrates the company's commitment to returning value to shareholders, though future dividends will remain subject to Board approval. Gilead Sciences continues its focus on developing innovative medicines for HIV, viral hepatitis, COVID-19, cancer, and inflammation, with operations spanning more than 35 countries worldwide.
Gilead Sciences (GILD) ha annunciato un aumento del 2,6% nel suo dividendo trimestrale in contante, che entrerà in vigore nel primo trimestre del 2025. Il nuovo dividendo sarà di $0,79 per azione di azioni ordinarie, pagabile il 28 marzo 2025, agli azionisti registrati al 14 marzo 2025.
L'aumento del dividendo dimostra l'impegno dell'azienda a restituire valore agli azionisti, sebbene i futuri dividendi rimarranno soggetti all'approvazione del Consiglio. Gilead Sciences continua a concentrarsi sullo sviluppo di medicinali innovativi per l'HIV, l'epatite virale, il COVID-19, il cancro e l'infiammazione, con operazioni che si estendono in oltre 35 paesi in tutto il mondo.
Gilead Sciences (GILD) ha anunciado un aumento del 2,6% en su dividendo en efectivo trimestral, que entrará en vigor en el primer trimestre de 2025. El nuevo dividendo será de $0,79 por acción de acciones ordinarias, que se pagará el 28 de marzo de 2025, a los accionistas registrados hasta el 14 de marzo de 2025.
El aumento del dividendo demuestra el compromiso de la empresa de devolver valor a los accionistas, aunque los futuros dividendos seguirán sujetos a la aprobación de la Junta. Gilead Sciences continúa enfocándose en el desarrollo de medicamentos innovadores para el VIH, hepatitis viral, COVID-19, cáncer e inflamación, con operaciones que abarcan más de 35 países en todo el mundo.
길리어드 사이언스(GILD)는 2025년 첫 분기부터 발효될 2.6%의 증가를 발표했습니다. 새로운 배당금은 주당 $0.79의 보통주 배당금으로, 2025년 3월 28일에 2025년 3월 14일 기준 주주에게 지급됩니다.
이번 배당금 증가는 주주에게 가치를 반환하겠다는 회사의 의지를 보여주지만, 향후 배당금은 이사회 승인에 따라 달라질 수 있습니다. 길리어드 사이언스는 HIV, 바이러스성 간염, COVID-19, 암 및 염증에 대한 혁신적인 의약품 개발에 집중하고 있으며, 전 세계 35개국 이상에서 활동하고 있습니다.
Gilead Sciences (GILD) a annoncé une augmentation de 2,6% de son dividende en espèces trimestriel, qui prendra effet au premier trimestre de 2025. Le nouveau dividende s'élèvera à 0,79 $ par action d'actions ordinaires, payable le 28 mars 2025, aux actionnaires inscrits au 14 mars 2025.
L'augmentation du dividende montre l'engagement de l'entreprise à restituer de la valeur aux actionnaires, bien que les dividendes futurs restent soumis à l'approbation du conseil d'administration. Gilead Sciences continue de se concentrer sur le développement de médicaments innovants pour le VIH, l'hépatite virale, le COVID-19, le cancer et l'inflammation, avec des opérations s'étendant sur plus de 35 pays dans le monde.
Gilead Sciences (GILD) hat eine Erhöhung von 2,6% bei seiner vierteljährlichen Bar-Dividende angekündigt, die im ersten Quartal 2025 in Kraft treten wird. Die neue Dividende beträgt 0,79 $ pro Aktie von Stammaktien und wird am 28. März 2025 an die Aktionäre ausgezahlt, die am 14. März 2025 registriert sind.
Die Erhöhung der Dividende zeigt das Engagement des Unternehmens, den Aktionären Wert zurückzugeben, obwohl zukünftige Dividenden weiterhin der Genehmigung des Vorstands unterliegen. Gilead Sciences konzentriert sich weiterhin auf die Entwicklung innovativer Medikamente gegen HIV, Virushepatitis, COVID-19, Krebs und Entzündung und ist in mehr als 35 Ländern weltweit tätig.
- 2.6% increase in quarterly dividend to $0.79 per share
- Continued commitment to shareholder returns through dividend program
- None.
Insights
Gilead's 2.6% dividend increase to
The new quarterly dividend implies an annualized payout of
For income-focused investors, the dividend increase, though smaller than historical averages, reinforces Gilead's position as a stable dividend-paying stock in the healthcare sector. The company's consistent dividend growth trajectory, albeit at a measured pace, demonstrates confidence in its underlying business model and long-term cash generation capabilities. This approach aligns with the broader trend among large-cap biopharma companies of maintaining sustainable payout ratios while preserving capital for growth initiatives.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in
For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).
View source version on businesswire.com: https://www.businesswire.com/news/home/20250211814563/en/
Ashleigh Koss, Media
public_affairs@gilead.com
Jacquie Ross, Investors
investor_relations@gilead.com
Source: Gilead Sciences, Inc.
FAQ
What is Gilead Sciences' (GILD) new quarterly dividend amount for 2025?
When will GILD's increased dividend be payable in 2025?
How much did Gilead Sciences (GILD) increase its dividend for Q1 2025?
What is the record date for GILD's Q1 2025 dividend payment?
